Hydroxyurea
- Generic Name
- Hydroxyurea
- Brand Names
- Droxia, Hydrea, Siklos, Xromi
- Drug Type
- Small Molecule
- Chemical Formula
- CH4N2O2
- CAS Number
- 127-07-1
- Unique Ingredient Identifier
- X6Q56QN5QC
- Background
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
- Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
- Associated Therapies
- Chemoradiotherapy, Radiation Therapy
Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Research Institute for Genetic and Human Therapy
- Target Recruit Count
- 225
- Registration Number
- NCT00002427
- Locations
- 🇺🇸
Albany Med College, Albany, New York, United States
🇺🇸Boulevard Comprehensive Care Ctr, Jacksonville, Florida, United States
🇺🇸Gary Blick MD, Stamford, Connecticut, United States
A Study of MKC-442 in Combination With Other Anti-HIV Drugs
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Registration Number
- NCT00002412
- Locations
- 🇺🇸
Dr Robert Wallace, St. Petersburg, Florida, United States
Safety and Effectiveness of a Combination Anti-HIV Drug Treatment
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 150
- Registration Number
- NCT00005018
- Locations
- 🇺🇸
East Bay AIDS Ctr, Berkeley, California, United States
🇺🇸Altamed Medical Health Services, Los Angeles, California, United States
🇺🇸Gary Richmond MD, Fort Lauderdale, Florida, United States
A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-06-07
- Target Recruit Count
- 900
- Registration Number
- NCT00000919
- Locations
- 🇺🇸
Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States
🇺🇸Marin County Specialty Clinic, San Rafael, California, United States
🇺🇸Emory Hemo Comp Evaluation Clinic / East TN Comp Hemo Ctr, Atlanta, Georgia, United States
A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 100
- Registration Number
- NCT00002230
- Locations
- 🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States
Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection
- Conditions
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002176
- Locations
- 🇺🇸
Univ of California at San Francisco Gen Hosp, San Francisco, California, United States
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2011-04-14
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00002177
- Locations
- 🇺🇸
Univ of California at San Francisco Gen Hosp, San Francisco, California, United States
A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 399
- Registration Number
- NCT00000916
- Locations
- 🇺🇸
Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸Weiss Memorial Hosp., Chicago, Illinois, United States
🇺🇸Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States
A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-29
- Target Recruit Count
- 150
- Registration Number
- NCT00000939
- Locations
- 🇺🇸
Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium, San Jose, California, United States
🇺🇸San Mateo AIDS Program / Stanford Univ, Stanford, California, United States
🇺🇸Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.